Clinical Trials · NCT01790126
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Aragon Pharmaceuticals, Inc.
- Enrollment
- 90
- Start date
- Mar 2013
- Locations
- 5 sites, United States
- Primary endpoint
- Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months